TY - JOUR
T1 - Merlin's tumor suppression linked to inhibition of the E3 ubiquitin ligase CRL4DCAF1
AU - Li, Wei
AU - Giancotti, Filippo G.
N1 - Funding Information:
We thank members of our laboratory for discussions. This work was sup ported by National Institutes of Health (NIH) Grant R01 CA152975 (to F.G.G.) and Cancer Center Support Grant P30 CA08748. W.L. is a recipient of the Young Investigator Award from the Children’s Tumor Foundation.
PY - 2010/11/15
Y1 - 2010/11/15
N2 - The mechanism by which the FERM domain protein Merlin, encoded by the tumor suppressor NF2, restrains cell proliferation is poorly understood. Prior studies have suggested that Merlin exerts its antimitogenic effect by interacting with multiple signaling proteins located at or near the plasma membrane. We have recently observed that Merlin translocates into the nucleus and binds to and inhibits the E3 ubiquitin ligase CRL4DCAF1. Genetic evidence indicates that inactivation of Merlin induces oncogenic gene expression, hyperproliferation, and tumorigenicity by unleashing the activity of CRL4DCAF1. In addition to providing a potential explanation for the diverse effects that loss of Merlin exerts in multiple cell types, these findings suggest that compounds inhibiting CRL4DCAF1 may display therapeutic efficacy in Neurofibromatosis type 2 and other cancers driven by Merlin inactivation.
AB - The mechanism by which the FERM domain protein Merlin, encoded by the tumor suppressor NF2, restrains cell proliferation is poorly understood. Prior studies have suggested that Merlin exerts its antimitogenic effect by interacting with multiple signaling proteins located at or near the plasma membrane. We have recently observed that Merlin translocates into the nucleus and binds to and inhibits the E3 ubiquitin ligase CRL4DCAF1. Genetic evidence indicates that inactivation of Merlin induces oncogenic gene expression, hyperproliferation, and tumorigenicity by unleashing the activity of CRL4DCAF1. In addition to providing a potential explanation for the diverse effects that loss of Merlin exerts in multiple cell types, these findings suggest that compounds inhibiting CRL4DCAF1 may display therapeutic efficacy in Neurofibromatosis type 2 and other cancers driven by Merlin inactivation.
UR - http://www.scopus.com/inward/record.url?scp=78649844484&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78649844484&partnerID=8YFLogxK
U2 - 10.4161/cc.9.22.13838
DO - 10.4161/cc.9.22.13838
M3 - Review article
C2 - 21084862
AN - SCOPUS:78649844484
SN - 1538-4101
VL - 9
SP - 4433
EP - 4436
JO - Cell Cycle
JF - Cell Cycle
IS - 22
ER -